IN2014MN01940A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01940A IN2014MN01940A IN1940MUN2014A IN2014MN01940A IN 2014MN01940 A IN2014MN01940 A IN 2014MN01940A IN 1940MUN2014 A IN1940MUN2014 A IN 1940MUN2014A IN 2014MN01940 A IN2014MN01940 A IN 2014MN01940A
- Authority
- IN
- India
- Prior art keywords
- getting
- risk
- cardiovascular event
- level
- neurotensin
- Prior art date
Links
- 230000007211 cardiovascular event Effects 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 108010054321 proneurotensin Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Abstract
Subject of the present invention is a method for predicting the risk of getting a cardiovascular event in a female subject comprising determining the level of pro neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of pro neurotensin or fragments thereof with the a risk for getting a cardiovascular event wherein an elevated level is predictive for an enhanced risk of getting a cardiovascular event.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261608376P | 2012-03-08 | 2012-03-08 | |
EP12158678 | 2012-03-08 | ||
EP12165057 | 2012-04-20 | ||
PCT/EP2013/054799 WO2013132088A1 (en) | 2012-03-08 | 2013-03-08 | A method for predicting the risk of getting a cardiovascular event in a female subject |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01940A true IN2014MN01940A (en) | 2015-07-10 |
Family
ID=49115969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1940MUN2014 IN2014MN01940A (en) | 2012-03-08 | 2013-03-08 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20150118236A1 (en) |
EP (1) | EP2823318B1 (en) |
JP (1) | JP6431373B2 (en) |
CN (1) | CN103308673B (en) |
IN (1) | IN2014MN01940A (en) |
RU (1) | RU2652304C2 (en) |
WO (1) | WO2013132088A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160097781A1 (en) * | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
SG10202003170YA (en) | 2015-02-27 | 2020-05-28 | Sphingotec Gmbh | A method for predicting the risk of obesity in a subject |
JP7411546B2 (en) | 2017-10-24 | 2024-01-11 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | Selenoprotein P for prediction of first cardiovascular event |
CN109678958B (en) * | 2019-01-31 | 2022-03-18 | 重庆探生科技有限公司 | Human NT-proBNP specific recombinant goat monoclonal antibody, and preparation method and application thereof |
RU2718285C1 (en) * | 2019-05-31 | 2020-04-01 | федеральное государственное бюджетное образовательное учреждение высшего образования "Новосибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НГМУ Минздрава России) | Method for prediction of stroke risk in men working under conditions of common vibration |
WO2022101937A1 (en) * | 2020-11-12 | 2022-05-19 | Shah Komal | An integrated health data capture and analysis based device for evaluation, diagnosis and prognosis of heart failure |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
US6352862B1 (en) * | 1989-02-17 | 2002-03-05 | Unilever Patent Holdings B.V. | Analytical test device for imuno assays and methods of using same |
US5736343A (en) * | 1995-08-18 | 1998-04-07 | Landry; Donald | Detection of organic compounds through regulation of antibody-catalyzed reactions |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
DK1531791T3 (en) | 2002-06-07 | 2010-11-01 | Dyax Corp | Prevention and restriction of ischemia |
US7634360B2 (en) * | 2003-09-23 | 2009-12-15 | Prediction Sciences, LL | Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof |
CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
EP1759214B1 (en) * | 2004-06-15 | 2013-04-24 | F.Hoffmann-La Roche Ag | The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication |
WO2006032436A2 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag. | Use of microproteins as tryptase inhibitors |
DE102005003687A1 (en) * | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunodiagnostic determination of neurotensin in mammal blood, comprises injecting immune active N-terminal mammal proneurotensin in to the serum- or plasma- sample |
EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
WO2010060748A1 (en) | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
ES2538002T3 (en) | 2009-01-07 | 2015-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treatment, prognostic evaluation and breast cancer detection |
EP2427764B1 (en) * | 2009-05-05 | 2017-07-26 | B.R.A.H.M.S GmbH | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
US8846414B2 (en) * | 2009-09-29 | 2014-09-30 | Advanced Liquid Logic, Inc. | Detection of cardiac markers on a droplet actuator |
US20120301393A1 (en) | 2009-12-14 | 2012-11-29 | Scil Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
CN105949301B (en) | 2010-06-08 | 2020-03-27 | 皮里斯制药有限公司 | Tear lipocalin muteins binding to IL-4 receptor α |
-
2012
- 2012-10-08 CN CN201210520697.6A patent/CN103308673B/en active Active
-
2013
- 2013-03-08 RU RU2014140430A patent/RU2652304C2/en active
- 2013-03-08 WO PCT/EP2013/054799 patent/WO2013132088A1/en active Application Filing
- 2013-03-08 IN IN1940MUN2014 patent/IN2014MN01940A/en unknown
- 2013-03-08 EP EP13708192.3A patent/EP2823318B1/en active Active
- 2013-03-08 US US14/383,425 patent/US20150118236A1/en not_active Abandoned
- 2013-03-08 JP JP2014560403A patent/JP6431373B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2823318A1 (en) | 2015-01-14 |
CN103308673A (en) | 2013-09-18 |
RU2652304C2 (en) | 2018-04-25 |
WO2013132088A4 (en) | 2013-11-07 |
WO2013132088A1 (en) | 2013-09-12 |
JP6431373B2 (en) | 2018-11-28 |
EP2823318B1 (en) | 2016-08-10 |
US20150118236A1 (en) | 2015-04-30 |
CN103308673B (en) | 2017-05-31 |
RU2014140430A (en) | 2016-04-27 |
JP2015511007A (en) | 2015-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01940A (en) | ||
HK1219010A1 (en) | System and method for detecting advertisements on the basis of fingerprints | |
EP2576837A4 (en) | Prostate cancer associated circulating nucleic acid biomarkers | |
BR112013032183A2 (en) | resource assessment system and method | |
WO2014200912A3 (en) | Mathematical processes for determination of peptidase cleavage | |
IL230896B (en) | Micro-rna biomarkers for use in determining the presence or risk of a pulmonary tumor or an aggressive pulmonary tumor | |
NZ630421A (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
MX370790B (en) | Threaded coupling for steel pipe. | |
WO2013159872A8 (en) | Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope | |
NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
WO2012135227A3 (en) | Methods and systems for assessing exposure to heavy metals | |
FR2992620B1 (en) | TRAIN AND METHOD FOR DETERMINING THE COMPOSITION OF SUCH A SAFETY TRAIN | |
WO2016066862A3 (en) | A method for predicting the risk of obesity in a subject | |
MX2022013471A (en) | Nucleic acid detection and quantification method and compositions. | |
IN2014MN01936A (en) | ||
FR2996192B1 (en) | METHOD FOR DETERMINING THE WEAR CONDITION OF A PIECE AND INFORMATION OF A CLIENT | |
MX2015015328A (en) | Detecting edge cracks. | |
PL3289096T3 (en) | Method for the prognosis and/or diagnosis of an illness based on a sample of adipose tissue | |
IN2015DN01646A (en) | ||
IN2014MN01937A (en) | ||
FR2996250B1 (en) | METHOD FOR IDENTIFYING AND / OR MONITORING THE DEFORMATION OF A TURBOMACHINE PIECE | |
WO2013106851A3 (en) | Syncollin, pancreatic triacylglycerol lipase, and other biomarkers for diabetes | |
WO2014023952A3 (en) | Interleukin-18 inhibitor for use in prevention and treatment of osteoarthritis | |
TR201901828T4 (en) | A method for predicting the risk of getting cancer or being diagnosed with cancer in a person. | |
EP3004846C0 (en) | A kit for detecting micro-rna extracted from a samlple of body fluid as well and a method for the detection thereof |